proxyvotesnow.com

Home › Companies › ESPERION THERAPEUTICS INC. › 2023-2024

ESPERION THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ESPERION THERAPEUTICS INC.’s Form 8-K, filed 2024-05-28 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 7Reported items
  • 112Asset managers
  • 361Fund votes
  • 2024-05-23Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ESPERION THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ESPERION THERAPEUTICS INC.

These tallies are ESPERION THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-28 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ESPERION THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-05-23
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Antonio M. Gotto Jr., M.D., D.Phil. 87,858,914---- 7,863,58044,073,687 Majority: yes
Elect Director: Nicole Vitullo 90,961,988---- 4,760,50644,073,687 Majority: yes
The Company's stockholders approved Proposal 2. 70,745,16424,537,427439,903 --44,073,687 Majority: yes
The Company's stockholders approved Proposal 3. 136,839,6072,422,428534,146 ---- Majority: yes
The Company's stockholders approved Proposal 4. 88,126,9937,007,381588,120 --44,073,687 Majority: yes
The Company's stockholders approved Proposal 5. 88,771,1866,425,073526,235 --44,073,687 Majority: yes

Source: ESPERION THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-05-28 — read the filing on EDGAR.

How asset managers voted at the ESPERION THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 112 asset managers that disclosed a ESPERION THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ESPERION THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve the non-binding advisory resolution on the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

76% fund support · no official result

FOR 76%AGAINST 24%

The 108 asset managers below cast 76% of the shares they voted on this item FOR (57,712,676 for, 18,462,988 against).

FOR: 57,712,676 (75.8%)AGAINST: 18,462,988 (24.2%)
Largest asset managers voting on “To approve the non-binding advisory resolution on the compensation of our named executive officers.” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ORBIMED ADVISORS LLC016,213,933 00Against
Woodline Partners LP10,810,4920 00For
WASATCH ADVISORS LP7,535,6270 00For
GREAT POINT PARTNERS LLC7,456,0000 00For
WASATCH FUNDS TRUST6,356,9890 00For
Vanguard6,333,3810 00For
DE Shaw4,357,2700 00For
Citadel2,571,3740 00For
Two Sigma2,132,1720 00For
BlackRock2,064,004269 00For
Goldman Sachs1,600,2500 00For
PLATINUM INVESTMENT MANAGEMENT LTD1,597,5420 00For
MARSHALL WACE, LLP01,425,133 00Against
JPMorgan1,311,4240 00For
JACOBS LEVY EQUITY MANAGEMENT, INC741,9980 00For
Wellington0445,605 00Against
GEODE CAPITAL MANAGEMENT, LLC316,9610 00For
Fidelity307,9340 00For
State Street303,6360 00For
Corient Private Wealth LLC239,0005,000 00For
NJ State Employees Deferred Compensation Plan195,1250 00For
BALYASNY ASSET MANAGEMENT L.P.0184,020 00Against
HighTower Advisors, LLC181,7510 00For
Northern Trust162,8230 00For
UBS142,4180 00For

Showing the 25 largest of 108 asset managers. See all 108 in the interactive database.

2. Election of Class II Directors: Antonio M. Gotto Jr., M.D., D.Phil.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%
FOR: 87,858,914WITHHELD: 7,863,580

ESPERION THERAPEUTICS INC.’s own tally for this item (“Elect Director: Antonio M. Gotto Jr., M.D., D.Phil.”): 87,858,914 for, 7,863,580 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,460,293 outstanding shares: 46.4% for, 4% withheld (50.5% of the company cast a for/withheld vote).

The 18 asset managers below cast 100% of the shares they voted on this item FOR (14,469,987 for, 0 against).

FOR 99.2%
FOR: 14,469,987 (99.3%)ABSTAIN: 102,309 (0.7%)
Largest asset managers voting on “Election of Class II Directors: Antonio M. Gotto Jr., M.D., D.Phil.” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST6,356,9890 00For
Vanguard6,295,3870 00For
JPMorgan1,197,0720 00For
Fidelity242,8430 00For
Lincoln Financial108,9190 00For
BlackRock83,3170 00For
Brighthouse47,5410 00For
Charles Schwab44,4380 00For
Blackstone Alternative Investment Funds00 42,5000Abstain
Russell Investments38,4990 00For
Principal Exchange-Traded Funds00 29,1510Abstain
Voya25,7820 00For
Nationwide6040 16,9270Abstain
Jacob Funds Inc.14,7250 00For
Equitable13,8710 00For
Victory Capital00 9,3400Abstain
Invesco00 2,6230Abstain
John Hancock00 1,7680Abstain

3. Election of Class II Directors: Nicole Vitullo

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 90,961,988WITHHELD: 4,760,506

ESPERION THERAPEUTICS INC.’s own tally for this item (“Elect Director: Nicole Vitullo”): 90,961,988 for, 4,760,506 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,460,293 outstanding shares: 48.0% for, 3% withheld (50.5% of the company cast a for/withheld vote).

The 18 asset managers below cast 100% of the shares they voted on this item FOR (14,572,296 for, 0 against).

FOR 100%
FOR: 14,572,296 (100.0%)
Largest asset managers voting on “Election of Class II Directors: Nicole Vitullo” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST6,356,9890 00For
Vanguard6,295,3870 00For
JPMorgan1,197,0720 00For
Fidelity242,8430 00For
Lincoln Financial108,9190 00For
BlackRock83,3170 00For
Brighthouse47,5410 00For
Charles Schwab44,4380 00For
Blackstone Alternative Investment Funds42,5000 00For
Russell Investments38,4990 00For
Principal Exchange-Traded Funds29,1510 00For
Voya25,7820 00For
Nationwide17,5310 00For
Jacob Funds Inc.14,7250 00For
Equitable13,8710 00For
Victory Capital9,3400 00For
Invesco2,6230 00For
John Hancock1,7680 00For

4. To approve an amendment to the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan.

COMPENSATION

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 18 asset managers below cast 100% of the shares they voted on this item FOR (14,572,296 for, 0 against).

FOR: 14,572,296 (100.0%)
Largest asset managers voting on “To approve an amendment to the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan.” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST6,356,9890 00For
Vanguard6,295,3870 00For
JPMorgan1,197,0720 00For
Fidelity242,8430 00For
Lincoln Financial108,9190 00For
BlackRock83,3170 00For
Brighthouse47,5410 00For
Charles Schwab44,4380 00For
Blackstone Alternative Investment Funds42,5000 00For
Russell Investments38,4990 00For
Principal Exchange-Traded Funds29,1510 00For
Voya25,7820 00For
Nationwide17,5310 00For
Jacob Funds Inc.14,7250 00For
Equitable13,8710 00For
Victory Capital9,3400 00For
Invesco2,6230 00For
John Hancock1,7680 00For

5. To approve an amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan.

COMPENSATION

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 18 asset managers below cast 100% of the shares they voted on this item FOR (14,572,296 for, 0 against).

FOR: 14,572,296 (100.0%)
Largest asset managers voting on “To approve an amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan.” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST6,356,9890 00For
Vanguard6,295,3870 00For
JPMorgan1,197,0720 00For
Fidelity242,8430 00For
Lincoln Financial108,9190 00For
BlackRock83,3170 00For
Brighthouse47,5410 00For
Charles Schwab44,4380 00For
Blackstone Alternative Investment Funds42,5000 00For
Russell Investments38,4990 00For
Principal Exchange-Traded Funds29,1510 00For
Voya25,7820 00For
Nationwide17,5310 00For
Jacob Funds Inc.14,7250 00For
Equitable13,8710 00For
Victory Capital9,3400 00For
Invesco2,6230 00For
John Hancock1,7680 00For

6. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 18 asset managers below cast 100% of the shares they voted on this item FOR (14,572,296 for, 0 against).

FOR: 14,572,296 (100.0%)
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fi” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST6,356,9890 00For
Vanguard6,295,3870 00For
JPMorgan1,197,0720 00For
Fidelity242,8430 00For
Lincoln Financial108,9190 00For
BlackRock83,3170 00For
Brighthouse47,5410 00For
Charles Schwab44,4380 00For
Blackstone Alternative Investment Funds42,5000 00For
Russell Investments38,4990 00For
Principal Exchange-Traded Funds29,1510 00For
Voya25,7820 00For
Nationwide17,5310 00For
Jacob Funds Inc.14,7250 00For
Equitable13,8710 00For
Victory Capital9,3400 00For
Invesco2,6230 00For
John Hancock1,7680 00For

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,221,302 for, 0 against).

FOR: 1,221,302 (100.0%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
JPMorgan1,221,2430 00For
TD ASSET MANAGEMENT INC590 00For

Largest ESPERION THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of ESPERION THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 189,460,293 shares outstanding at the time of that meeting.

Top ESPERION THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1ORBIMED ADVISORS LLC 8.56%
2Woodline Partners LP 5.71%
3WASATCH ADVISORS LP 3.98%
4GREAT POINT PARTNERS LLC 3.94%
5WASATCH FUNDS TRUST 3.36%
6Vanguard 3.34%
7DE Shaw 2.30%
8Citadel 1.36%
9Two Sigma 1.13%
10BlackRock 1.09%

Reported ESPERION THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ESPERION THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
BlackRock 7.83% 13F
Vanguard Group 6.38% 13F
BB Biotech AG 4.85% 13G
Millennium Management 3.00% 13F
D.E. Shaw 2.71% 13F
Morgan Stanley 2.14% 13F
Two Sigma 2.10% 13F
Citadel Advisors 1.98% 13F
Renaissance Technologies 1.12% 13F
Geode Capital 0.93% 13F

Percentages above are of 189,460,293 shares outstanding, as reported by ESPERION THERAPEUTICS INC. on its Form 10-Q dated 2024-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ESPERION THERAPEUTICS INC.’s 10-Q dated 2024-05-01. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ESPERION THERAPEUTICS INC.'s shareholder meeting held 2024-05-23, in the 2023-2024 proxy season, 112 asset managers reported how they voted in their SEC Form N-PX filings, covering 361 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ESPERION THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve the non-binding advisory resolution on the compensation of our named executive… — the reporting funds cast 76% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

ESPERION THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.